Domain dossier

Validating and quality-controlling tumor-informed ctDNA MRD assays

Adaptation note, read this first. idea-003's target: is RUO (research use only), not a patient population, and its buyer is a molecular laboratory, not a clinician or a patient. The _template.md sections were written for a patient-population domain (epidemiology, care pathway, user groups, standard of care) and are adapted here rather than forced: Section 1 covers testing volume and the number/growth of tumor-informed MRD assays and the labs running them, not disease prevalence. Section 2 ("care pathway") is read as the lab workflow step a reference-material panel sits in — assay development bench work, analytical validation, then ongoing daily/lot QC — not a clinical site of care. Section 3 ("user groups") separates the molecular lab director/assay developer (buyer) from the CLIA lab operator (daily user) from the assay manufacturer (the downstream commercial customer whose own analytical-validation needs define what the reference material must match). Section 6 ("reimbursement") is genuinely not applicable to an RUO laboratory consumable — nobody bills a payer for it — and that is stated plainly rather than left silently blank, the same disposition idea-003's own Scorer and Verifier already recorded for its Factor 2.

This dossier is thinnest exactly where a patient-population dossier would be thickest (epidemiology, care pathway, reimbursement) and thickest exactly where this domain's real decision evidence lives: Section 5, the reference-material vendors and the MRD assays that consume their output, worked hardest per the research-lane spec.

This file carries no confidence tags. Every line below is context with a source attached. To affect a score, a line must be copied into a candidate's ## Claims as unverified via engine/scripts/append_research_claims.py and pass the Verifier or a future Corroborator. See README.md in this directory.

---

1. Condition & epidemiology

as_of: 2026-08-27 · sources searched: connectors literature (multiple queries, see §10), directly-fetched company investor-relations press releases and an earnings-call transcript · not searched: a systematic enumeration of every US laboratory offering a tumor-informed MRD assay; non-Medicare/non-commercial test volumes

Adapted meaning of "epidemiology" here: testing volume and market growth, not disease prevalence. The clinical prevalence of the underlying cancers (largely stage II-III colorectal cancer to date) is Section 4's subject, not this section's.

Verbatim:

"Clinical molecular residual disease (MRD) oncology units grew 34,000 units over the first quarter of 2026, the largest sequential increase to-date." — Natera, Inc., Q2 2026 financial results press release, dated 2026-08-06 [18]

"Reveal continues to perform at an extremely high level with volume growth accelerating for the third quarter in a row to well above 100% year-over-year." — Guardant Health Q2 2026 earnings call, 2026-07-30 [19]

Read this narrowly. Neither figure is an absolute quarterly MRD test count independently confirmed by this pass — the 1,043,900/1,030,100 figures are Natera's total company test volume across all product lines (women's health, organ health, oncology, MRD combined), and the specific absolute Signatera-MRD-unit count reported by secondary financial media (approximately 283,000 units) was not independently confirmed by a direct fetch of a primary Natera document in this pass — it is recorded here as not retrieved, not as a finding, and must not be treated as one. The Guardant figure is a growth rate stated verbatim by management on an earnings call, not an absolute unit count; Guardant's own Q2 2026 press release (fetched directly) does not mention Reveal or MRD volumes at all, which is itself worth recording — the growth figure lives in the call transcript, not the press release.

Gaps: no enumeration of how many US laboratories run or are developing a tumor-informed MRD assay was found (the "30-60 laboratories" figure idea-003 claim 12 uses is the Generator's own unsourced estimate, already flagged unconfirmed/permanently unverifiable in that file); no absolute, independently-confirmed Signatera or Reveal MRD-specific test count for any quarter.

2. Care pathway & clinical setting

as_of: 2026-08-27

Adapted meaning: a laboratory workflow step, not a clinical site of care. A commutable reference-material panel sits at three points in a molecular laboratory's workflow, not in a clinical pathway: (a) assay development bench work, where the developer establishes a limit of detection and characterizes the analytical measurement range; (b) formal analytical validation ahead of clinical launch or a CAP/CLIA inspection; (c) ongoing lot-to-lot and daily quality control once the assay is running clinically (the CLIA-mandated control-procedure requirement below). No connector or search in this repo addresses laboratory bench workflow directly; what is established instead is the regulatory floor that makes step (c) recurring rather than optional.

Regulatory context carried here because it recurs across this domain's candidates, not because it is un-established: idea-003's own Claims and Verifier passes already established, via the same regulation (eCFR) connector re-run fresh for this dossier, that 42 CFR 493.1256 (CLIA) requires "for each test system, the laboratory is responsible for having control procedures that monitor the accuracy and precision of the complete analytic process," and that "[a]t least once each day patient specimens are assayed or examined," each molecular amplification procedure must include control materials [14]. That regulation says nothing about whether the control material must be purchased from a third party or built in-house — a limit already recorded in idea-003 and not re-litigated here.

Gaps: no direct source on turnaround time, staffing, or bench sequencing for a tumor- informed MRD assay run (tumor-tissue whole-exome/whole-genome sequencing to identify a patient-specific variant panel, then serial plasma draws against that panel) was searched this pass.

3. User groups & incentives

as_of: 2026-08-27

Four separate roles, adapted from the patient-population template's five:

Gaps: the purchasing role — whether the buyer is the same person who runs the daily control procedure, and whether purchasing this consumable requires a capital-procurement process or is a bench-level consumable order — was not independently sourced this pass; idea-003's deck- surfaced assumption on this remains unverified and unresourced here.

4. Standard of care & clinical evidence

as_of: 2026-08-27 · sources searched: connectors literature + literature-detail on 13 PMIDs (see §10) · not searched: guideline society statements (ASCO, NCCN) directly; CAP/CLIA proficiency-testing program specifics (paywalled/member-only, not attempted)

What "standard of care" means in this domain: whether tumor-informed ctDNA MRD testing changes management, and what analytical performance the assays that use this reference material claim for themselves. Two distinct evidence threads: (a) clinical validity of ctDNA-guided management in colorectal cancer, and (b) analytical validation of the assays themselves — the latter is what tells a reference-material maker what range it needs to cover.

4a. Clinical validity — colorectal cancer surveillance and ctDNA-guided treatment

Verbatim:

"Among 968 evaluable patients, 702 (72.5%) were ctDNA negative... ctDNA-negative patients experienced significantly fewer recurrences than ctDNA-positive patients (3-year RFS 87% versus 49%; P < 0.001)... In ctDNA-negative patients, de-escalation reduced oxaliplatin use (34.8% versus 88.6%) and hospitalizations (8.5% versus 13.2%) but yielded slightly lower RFS than standard management (85.3% versus 88.1%), not meeting the non-inferiority margin." — PMID 41115959 (DYNAMIC-III) [8]

"Median DFS was 9.30 months with FTD/TPI and 5.55 months with placebo (hazard ratio = 0.79, 95% confidence interval: 0.60-1.05, P = 0.107), and the primary endpoint was not met." — PMID 42260101 (ALTAIR) [9]

Known negative/equivocal findings, recorded with the same weight as the positive ones: ALTAIR's negative primary endpoint [9] and DYNAMIC-III's failure to meet its de-escalation non-inferiority margin [8] are exactly the kind of finding a title alone would not surface — both are read at full abstract depth here, not from a headline. ctDNA status is validated as strongly prognostic in this evidence base; whether acting on a positive result (escalating or intervening) improves outcomes is, on the two largest randomized trials located this pass, not yet demonstrated.

4b. Analytical validation of the assays this reference material would serve

This is the load-bearing evidence for what an assay-validation reference panel must be able to do — the LOD and VAF range each commercial or published tumor-informed assay claims for itself.

Verbatim:

"Haystack MRD demonstrated a 95% limit of detection of 0.063 mean ctDNA molecules/mL and an analytical measurement range of 0.25-1,000 mean ctDNA molecules/mL." — PMID 42624249 [1]

"The analytical validation result of CancerDetect™ showed limit of detection successfully reached down to 0.001% (10-5) with 99.9% specificity." — PMID 41212866 [2]

"Analytical measurements demonstrated a detection threshold of 1.67 parts per million (PPM) with a limit of detection at 95% (LOD95) of 3.45 PPM." — PMID 38484152 [3]

"Limit of detection ranged from 0.008% allele frequency when utilizing 60 ng of cfDNA input with 18-50 variants in the patient-specific panels (> 99.9% sensitivity)... to 0.05% allele frequency when using 10 ng of cfDNA input with an 18-variant panel." — PMID 37632661 [4]

"umiVar enabled variant detection at a limit of detection as low as 0.0017%, with no false positive calls in mutation-free reference samples." — PMID 40866952 [13]

Read this against idea-003's own stated target range. The candidate's mechanism targets "0.001%-0.5% VAF." The published assay landscape above spans 0.000345% to 0.5%+ across five distinct commercial/research methods, using inconsistent units (molecules/mL vs. VAF percent vs. ppm) that are not directly interconvertible without knowing the total cfDNA input mass per assay — a real complication for any single reference-material panel claiming to serve "the MRD assay market" as a monolithic target. The bottom of the candidate's target range overlaps the more aggressive published assays' claimed LODs; the top of its range (0.5%) is comfortably inside what commercial reference vendors already characterize (see §5).

Gaps: no guideline (NCCN, ASCO) position statement was independently retrieved this pass — the trial evidence above is read directly, not through a guideline's summary of it. CAP/CLIA proficiency-testing program specifics for ctDNA MRD assays (as opposed to the general EQA literature in §5) were not searched — CAP program materials sit behind a member paywall this pass did not attempt to breach.

5. Reference products — and why people stop using them

as_of: 2026-08-27 · sources searched: connectors literature/literature-detail; direct WebFetch of vendor product pages, FAQ pages, and one vendor flyer; direct WebFetch of company investor-relations press releases and one earnings-call transcript · not searched: MAUDE (no connector — RUO/LDT materials and assays are not device-cleared, so MAUDE would be silent by construction the same way idea-003 already reasoned about clearances/recalls); independent third-party head-to-head commutability studies comparing the three named vendors

The load-bearing section, worked hardest per the research-lane spec. The "incumbent" here is not one product but three named commercial reference-material vendors (idea-003's predicate_or_analog), plus the assay manufacturers who are the panel's actual downstream economic beneficiary.

Seraseq® ctDNA Reference Materials (LGC Clinical Diagnostics, formerly SeraCare)

• What it is: a contrived reference-material product line for validating NGS- and ddPCR-based ctDNA assays. LGC acquired SeraCare Life Sciences in November 2018; SeraCare's NGS-genomics reference-material brand became part of "LGC Clinical Diagnostics."
• Matrix: the current v4 AF0.1% product's own page describes the matrix as a **"plasma like matrix"** — not stated to be pooled human donor plasma.
• Lowest characterized allele fraction (vendor-labeled): 0.1% VAF for the ctDNA v4 line (four levels: WT/0%, 0.1%, 0.5%, 5%); the ctDNA Complete™ line's lowest non-zero level is also 0.1% (six levels: WT, 0.1%, 0.5%, 1%, 2.5%, 5%).
• Evidence behind it: described on the vendor page as "orthogonally validated truth-set materials"; no independent third-party validation study of this specific product was located this pass.
• Adoption: not established by this pass — no independent sales, installed-base, or citation-count figure was found.
• Abandonment record — why people stop:

• Verbatim:

"The product uses a 'Plasma like matrix' rather than actual human donor plasma or other specified contrived formulations." — WebFetch summary of LGC/SeraCare Seraseq ctDNA Reference Material v4 AF0.1% product page, fetched 2026-08-27 [15]

"Seraseq ctDNA v4 is manufactured with a new fragmentation process which results [in] lower background than previous Seraseq ctDNA offerings to support greater confidence at low variant allele frequencies." — same product page [15]

"We are excited to welcome SeraCare to our Standards division." — Euan O'Sullivan, Managing Director, LGC's Standards division, LGC press release dated 2018-11-26 [20]

Gaps: no independent (non-vendor) commutability study of Seraseq ctDNA v4 against real patient plasma was located. Whether "plasma like matrix" retains native cell-free DNA fragmentomics (the specific differentiator idea-003 claims) or is a wholly synthetic construct is not resolved by the vendor's own page language.

Horizon Discovery / Revvity HDx cfDNA Reference Standards

• What it is: a cfDNA reference-standard product family (Mimix™/Multiplex I, Multiplex II, OncoSpan, and others) manufactured by Horizon Discovery, now part of Revvity.
• Matrix: the vendor's own FAQ page states the standards are **"derived from engineered human cell lines"** — fragmented human genomic DNA, average fragment size ~160 bp — **spiked into a synthetic plasma matrix** for the Matrix I/II product formats. Not pooled human donor plasma with native cell-free DNA.
• Lowest characterized allele fraction (vendor-labeled): "as low as 0.1 percent," matched with a wild-type control.
• Evidence behind it: vendor page states the standards support development, validation, and "demonstration of the performance of cfDNA assays and platforms on a routine basis"; no independent third-party validation study specific to this product was located this pass.
• Adoption: not established this pass.
• Abandonment record — why people stop: see the shared cross-vendor finding [12] above (precision below 0.5% VAF); no vendor-specific discontinuation record was located.
• Verbatim:

"Derived from engineered human cell lines" and provided as "fragmented human genomic DNA (average size 160 bp) resembling cell tumor DNA derived from human plasma." — Horizon Discovery "What are cfDNA Reference Standards?" FAQ page, fetched 2026-08-27 [16]

"Available at allelic frequencies down to 0.1% across a range of variants with a matched wild type." — same page [16]

"No commutability statement is provided" — this pass's own reading of the fetched page content; recorded as an absence, not a finding [16]

Gaps: no independent commutability study located; matrix composition (synthetic plasma, not native donor plasma) is stated by the vendor itself, which is directly relevant to idea-003's claimed differentiator but is not itself evidence that the synthetic matrix under-performs a native-plasma matrix — that comparison was not located this pass.

Twist Bioscience cfDNA Reference Standards

• What it is: the Twist cfDNA Pan-Cancer Reference Standard (v2), covering 400+ variant sites across 84 genes, marketed for liquid-biopsy and MRD assay development.
• Matrix: a Twist-published flyer describes the company's own contrived-specimen methodology (for a related MRD panel product, not necessarily identical to the reference standard itself) as **"blending synthetic variant sequences with fragmented cell line gDNA"** — again not pooled native donor plasma.
• Lowest characterized allele fraction: the reference standard is sold across multiple VAF levels; the specific lowest vendor-labeled level was not independently confirmed by a directly-fetched primary document this pass (a technical variant-list PDF exists but did not render as readable text to this pass's tools — recorded as not retrieved, not as "no low level exists"). Independently, a peer-reviewed benchmarking study reported reaching 0.0017% VAF using Twist's reference standard as one of three inputs to a research assay's own dilution/method, which is a researcher's achieved detection floor using the material, not the vendor's own labeled specification [13].
• Evidence behind it / Adoption: not established this pass beyond the benchmarking use in [13].
• Abandonment record — why people stop: not found; no vendor-specific discontinuation record located. Shared cross-vendor precision-degradation finding [12] applies here as general domain context, not as a Twist-specific finding (that study used a different, independently-manufactured multiplex cfDNA reference material, not a Twist product).
• Verbatim:

"[creating] contrived specimens by blending synthetic variant sequences with fragmented cell line gDNA" — WebFetch summary of a Twist Bioscience flyer, fetched 2026-08-27 [17]

Gaps: the vendor's own lowest labeled VAF for this specific SKU was not independently confirmed (PDF rendering failure, recorded honestly as not retrieved); no independent commutability study located.

Cross-vendor finding — precision degradation below 0.5% VAF, independent of any single vendor

• What it establishes: across eight domestic NGS-based cancer IVD manufacturers tested against a common multiplex cfDNA reference material (not one of the three vendors above, but directly on point for the mechanism question idea-003 claim 16 raises), "[t]he coefficient of variation (CV) was increased with decreasing mutant allelic frequency, and poor repetition occurred when the allelic frequency was lower than 0.5%."
• Source: [12], Journal of Cancer, 2018, n=8 manufacturers, 4 NGS platforms (NextSeq, HiSeq, Ion Proton, BGISEQ), reference materials at serial allelic frequencies from ~2% down to 0.1%.
• Verbatim:

"The coefficient of variation (CV) was increased with decreasing mutant allelic frequency, and poor repetition occurred when the allelic frequency was lower than 0.5%." — PMID 30405853 [12]

Read this against idea-003's claim 16 (the Poisson-limited-imprecision risk, previously recorded as entirely unsourced — "no connector verifies a physical claim"). This is an independently published, quotable finding that a comparable reference-material class shows degraded repeatability specifically below 0.5% VAF, across multiple platforms and manufacturers. It does not resolve claim 16's specific 0.001%-0.01% VAF sub-range (this study's lowest tested level was 0.1%, not the candidate's target floor), and it is not a bench study of this candidate's own proposed material — but it is real, independently retrieved, class-2 evidence bearing directly on the mechanism-risk factor that was previously recorded as having no evidence in either direction.

External quality assurance — a related but distinct signal

• What it establishes: in an 89-laboratory pilot EQA program using contrived reference material at predicted VAFs of 0.5%-2.5%, "88 of the 89 laboratories" returned results, and "Z-score proficiency testing found that >92% of clinical laboratories were concordant."
• Source: [6], Pathology Oncology Research, 2020, n=89 laboratories (China, Australia, New Zealand), reference material at 6 genotypes across 4 genes (EGFR, KRAS, BRAF, NRAS).
• Verbatim:

"Predicted genotypic variant allelic frequencies ranged between 0.5% - 2.5%... The average consensus data for each cfDNA genotype identified allelic frequencies ranging between 0.39%

• 4.4%... Z-score proficiency testing found that >92% of clinical laboratories were

concordant." — PMID 31487000 [6]

Read this narrowly, the discipline this section requires. This is the closest thing found this pass to independent evidence of the white space idea-003 claim 17 asserts (no product characterized in the sub-0.01% VAF MRD range): a real, published multi-laboratory EQA program existed and its reference material's operating range (0.39%-4.4% VAF) sits entirely above the candidate's target range (0.001%-0.5%), and above two of the three named vendors' own lowest labeled level (0.1%). This is evidence the general EQA/reference-material field currently operates well above MRD-range sensitivity, which supports the white-space claim without answering the class-3 question of whether any lab would buy a product that closed it.

No commercial reference product's discontinuation, recall, or withdrawal from distribution was located for any of the three named vendors. This is recorded as not found, not as "none exists" — a discontinuation record for an RUO reagent (as opposed to a cleared device) is not the kind of fact any US federal registry captures, and no vendor press archive was searched specifically for a product-line sunset announcement.

6. Reimbursement landscape

as_of: 2026-08-27

Genuinely not applicable, stated explicitly rather than left blank. This is a laboratory reagent/consumable sold to CLIA laboratories and assay manufacturers as an operating input, the same disposition idea-003's own Stage 2 Scorer and Stage 4 Verifier already recorded for its Factor 2 ("no referent... nobody bills a payer for an RUO quality-control reagent"). No HCPCS or CPT code applies to the reference material itself. The only reimbursement-adjacent fact in this domain is indirect and belongs to the downstream MRD test the reference material validates (CPT 0340U for Signatera, and the MolDX coverage article for tumor-informed MRD testing), both of which are already fully worked in idea-003's own Claims (claims 8-13) and are not re-derived here to avoid duplicating a candidate-specific pass in a file meant to outlive one candidate.

Gaps: none beyond the structural inapplicability stated above.

7. Technology trajectory

as_of: 2026-08-27

Constraint carried from the template: a counted series (clearances per year, entrants per year) cannot carry a confidence tag anywhere in this repo (docs/backlog.md 1.10); nothing of that shape is asserted here.

Gaps: no bench-level uncertainty-budget study (dPCR replicate series at stated DNA input mass) was located or is expected to exist as a published, citable source — idea-003's own Verifier already recorded this as a bench question no connector or literature scan settles, and this pass's literature search for "digital PCR uncertainty measurement ultra-low allele fraction circulating tumor DNA" returned zero PubMed records, confirmed not found, not merely not searched.

8. Market players & dynamics

as_of: 2026-08-27

Gaps: no funding-round, IPO, recall, or exit event for any of the three named reference-material vendors was located this pass — the search effort concentrated on product specification and analytical performance rather than corporate-transaction history beyond the one located acquisition (LGC/SeraCare, 2018).

9. Open questions — and what would settle them

Class-3 substitution performed this pass, stated plainly: the underlying question behind idea-003's claim 21 ("would labs prefer a third-party panel to in-house controls?") was not answered. Its revealed-behaviour twin — a documented vendor discontinuation or a published lab complaint driving a workaround — was searched for specifically and came up empty, which is itself the honest result of this pass, not a substitute answer to the original question. This differs from the potassium-monitoring-ckd dossier's experience with the same maneuver (§3.1 of docs/research-lane-spec.md), where a revealed-behaviour twin (RAASi discontinuation rates) was found; here, no twin was found, and that absence is recorded rather than papered over with the general precision-degradation finding, which is adjacent but is not itself a switching decision.

10. Provenance & staleness

What this dossier has never looked at, as of 2026-08-27 (first pass): any non-US regulatory or reimbursement framework (this dossier is US-scoped per its frontmatter, per every connector in this repo); a systematic enumeration of US laboratories running tumor-informed MRD assays; SEC filings (10-K/10-Q) for Natera or Guardant, as opposed to press releases and an earnings-call transcript; CAP Molecular Pathology checklist or ISO 17034 text directly (both sit behind access barriers this pass did not attempt to cross); MAUDE (no connector exists, and would be silent by construction for RUO/LDT material in any case); fda.gov guidance documents (the 2013 RUO/IUO distribution guidance central to idea-003 claims 2-3 remains unretrieved here exactly as it does there — this dossier does not duplicate that already-documented structural gap); veterinary data (out of scope by design, no US federal dataset exists for it in any domain). This is a first-pass dossier, built in one research-lane session — it is a starting point for the next candidate in this domain, not the output of a completed research program.

---

Sources

[1] Highly Accurate Detection of Circulating Tumor DNA for Monitoring Minimal Residual Disease in Solid Tumors: Analytical and Clinical Validation of the Haystack MRD Assay. The Journal of Molecular Diagnostics, 2026 Aug 20. PMID 42624249.

[2] Analytical validation of a hybrid-approach combining tumor-informed and tumor-agnostic bespoke ctDNA panel assay for the sensitive detection of minimal residual disease. PLoS ONE,

1. PMID 41212866.

[3] Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay. Oncotarget, 2024 Mar 14. PMID 38484152.

[4] Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors. Molecular Diagnosis & Therapy, 2023 Nov. PMID 37632661.

[5] Harmonising ctDNA Measurement in Haematological Malignancies: Traceability, Commutability and Reporting. Diagnostics (Basel), 2026 Apr 1. PMID 41975767. (Title/abstract read; haematological-malignancy scope noted, not directly applied to a solid-tumor MRD claim in this dossier.)

[6] External Quality Assurance of Current Technology for the Testing of Cancer-Associated Circulating Free DNA Variants. Pathology Oncology Research, 2020 Jul. PMID 31487000.

[7] A pilot plasma-ctDNA ring trial for the Cobas® EGFR Mutation Test in clinical diagnostic laboratories. Clinical Chemistry and Laboratory Medicine, 2019 Apr 24. PMID 30267626. (No abstract available in the PubMed record; recorded for completeness of the EQA/ring-trial landscape search, not as a source of any quantitative claim in this dossier.)

[8] Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial. Nature Medicine, 2025 Dec. PMID 41115959.

[9] Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial (ALTAIR, CIRCULATE-Japan). Nature Medicine, 2026. PMID 42260101. ClinicalTrials.gov identifier NCT04457297.

[10] Utility of circulating tumor DNA to detect minimal residual disease in colorectal cancer: A systematic review and network meta-analysis. International Journal of Cancer, 2025. PMID 40293388.

[11] Prognostic role of postoperative circulating tumor DNA in metastatic colorectal cancer treated with curative intent: A systematic review and meta-analysis. Cancer Treatment Reviews, 2026. PMID 42217424.

[12] Multiplex Cell-Free DNA Reference Materials for Quality Control of Next-Generation Sequencing-Based In Vitro Diagnostic Tests of Colorectal Cancer Tolerance. Journal of Cancer,

1. PMID 30405853.

[13] GeneBits: ultra-sensitive tumour-informed ctDNA monitoring of treatment response and relapse in cancer patients. Journal of Translational Medicine, 2025 Aug 27. PMID 40866952.

[14] 42 CFR 493.1256, "Standard: Control procedures" — retrieved via python3 -m connectors regulation 493.1256 --title 42 --expect "control procedures" --jurisdiction US, status verified, source_ref "eCFR versioner title-42, issue 2026-08-13, section=493.1256", re-run fresh for this dossier on 2026-08-27.

[15] LGC/SeraCare, "Seraseq® ctDNA Reference Material v4 AF0.1%" product page, https://www.seracare.com/Seraseq-ctDNA-Reference-Material-v4-AF01-0710-3992/, fetched 2026-08-27.

[16] Horizon Discovery (Revvity), "What are cfDNA Reference Standards?" FAQ page, https://horizondiscovery.com/en/frequently-asked-questions/reference-standards/what-are-cfdna-reference-standards, fetched 2026-08-27.

[17] Twist Bioscience, "High sensitivity detection of ultra low-frequency somatic mutations for minimal residual disease monitoring" (flyer), https://www.twistbioscience.com/resources/flyer/high-sensitivity-detection-ultra-low-frequency-somatic-mutations-minimal-residual, fetched 2026-08-27.

[18] Natera, Inc., "Natera Reports Second Quarter 2026 Financial Results," press release dated 2026-08-06, https://investor.natera.com/news/news-details/2026/Natera-Reports-Second-Quarter-2026-Financial-Results/default.aspx, fetched 2026-08-27.

[19] Guardant Health, Inc., Q2 2026 earnings call transcript, call held 2026-07-30, published by The Motley Fool, https://www.fool.com/earnings/call-transcripts/2026/08/07/guardant-health-gh-q2-2026-earnings-call-transcript/, fetched 2026-08-27.

[20] LGC, "LGC Acquires Seracare Life Sciences, Strengthening Its Position in Clinical Quality Control Tools," press release dated 2018-11-26, https://www.seracare.com/about-seracare/press-releases/lgc-acquires-seracare-life-sciences-strengthening-its-position-in-clinical-quality-control-tools/, fetched 2026-08-27.